{"entity":{"id":"allogene","kind":"company","name":"Allogene Therapeutics","aka":[],"tldr":"Allogeneic CAR-T leader: cema-cel (CD19) as MRD-guided first-line consolidation in lymphoma, and ALLO-316 (CD70) with responses in kidney cancer.","summary":"Allogene Therapeutics, based in South San Francisco and listed as ALLO, is the allogeneic CAR-T leader, with cema-cel, a CD19 CAR-T, positioned as MRD-guided first-line consolidation in lymphoma and ALLO-316, a CD70 CAR-T, showing responses in kidney cancer. Cema-cel received RMAT and Fast Track designations in July 2026 for MRD-positive large B-cell lymphoma after first-line therapy in the ALPHA3 trial, ALLO-316 gave a 31 percent confirmed response rate in CD70-high clear-cell renal cell carcinoma in the TRAVERSE trial in 2025. OnCo links it to diffuse large B-cell lymphoma and renal cell carcinoma, to allogeneic cell therapy, to CD19 and CD70 as targets and to the UCART19 paper. Whether treating MRD-positive patients before relapse improves outcomes is the question ALPHA3 will answer. Manufacturing cost and time is the bottleneck off-the-shelf cells are meant to relieve.","asOf":"2026-09-04","links":[{"label":"Cema-cel RMAT","url":"https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-receives-fda-regenerative-medicine-0"}],"tags":[],"related":[],"cancers":["dlbcl","rcc"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":["cd19","cd70"],"drugs":["allo-647"],"companies":[],"institutions":[],"pathways":[],"terms":["mrd"],"trials":["nct04416984","nct06500273"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"cell-therapy","website":"https://allogene.com","ticker":"ALLO","investors":[],"funding":[]},"route":"/companies/allogene/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"allogeneic-cell-banks","kind":"technology","name":"Allogeneic cell banks: one donor, hundreds of doses","route":"/technologies/allogeneic-cell-banks/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/"}],"drug":[{"id":"allo-647","kind":"drug","name":"ALLO-647","route":"/drugs/allo-647/"}],"term":[{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"trial":[{"id":"nct06500273","kind":"trial","name":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","route":"/trials/nct06500273/"},{"id":"nct04416984","kind":"trial","name":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","route":"/trials/nct04416984/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"paper":[{"id":"paper-ucart19-allogeneic-car-t-lancet-2020","kind":"paper","name":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL","route":"/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/"}],"company":[{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/"}]}}